• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    High Purity New England Bolsters Biopharma Solutions Services

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    Covectra Introduces Next-Gen Serialization Solution
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing

    Stevanato Group Launches AI Platform
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Almac Group

    test company saurabh

    Reed-Lane

    Aphena Pharma Solutions

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Adare Pharma Solutions

    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    GRAM Continues Aggressive Expansion in Parenterals

    Backed by Arlington Capital Partners, Grand River Aseptic Manufacturing invests in major expansion of capacity and capabilities with new fill finish facility

    GRAM Continues Aggressive Expansion in Parenterals
    GRAM's new aseptic processing facility expansion more than doubles its space. (Photo courtesy of GRAM)
    Tim Wright, Editor, Contract Pharma04.01.20
    Grand River Aseptic Manufacturing (GRAM) is a fast-growing contract development and manufacturing organization (CDMO) that provides sterile parenteral solutions to the pharmaceutical industry.

    It was back in 2017 when the Grand Rapids, MI-based CDMO’s aggressive growth trajectory really kicked into gear. At that time, Arlington Capital Partners, a private equity firm in the Washington, D.C. area, made a majority investment in GRAM.

    The seeds of Arlington’s funding have been coming to fruition since.

    Together, GRAM and Arlington have invested $60 million in a brand-new facility to increase its footprint. This aseptic processing facility expansion more than doubles GRAM’s existing square footage to over 100,000 square feet and provides access to top-quality, high-speed, state-of-the-art parenteral drug manufacturing and packaging for all commercial batch sizes.

    The new larger scale facility—within sight of GRAM’s primary location—will accommodate increasing, industry-wide demand for cGMP parenteral drug manufacturing, analytical testing, and regulatory filing services.

    Contract Pharma recently talked about GRAM’s growth, the new greenfield facility and the new equipment housed in it with Malcolm Little, partner at Arlington and GRAM board director, and GRAM’s vice president of finance, Nick Bykerk.

    Contract Pharma (CP): What was the drive behind GRAM’s investment in the new facility?

    Malcolm Little:
    At the onset of our partnership with GRAM, Arlington Capital Partners identified a significant supply and demand imbalance existing in the aseptic fill-finish market—specifically in the U.S., but globally as well. GRAM was, and is, uniquely positioned to serve as a platform for rapid expansion by upholding the quality standards and exemplary culture that is already instilled in the company. The demand for GRAM’s services was well in excess of the business’ existing footprint, so the opportunity to invest in the business to facilitate its rapid expansion was attractive. 

    Nick Bykerk: Early on, we identified the unique opportunity to build a truly state-of-the-art facility from the ground up and specifically design it to serve the growing pharmaceutical market. Designing GRAM’s new facility from the ground up allowed us to focus on the processes and equipment that will provide the most benefit to our clients while putting us on the forefront of technology and regulatory trends. Deciding upon facility layout and equipment first, then building the facility around it, allows us to concentrate on innovations that lead to the highest quality products, and gives us the ability to adapt to the ever-changing regulatory environment. 

    CP: What makes the facility unique?

    Nick Bykerk:
    In addition to the design-build concept that further meets growing market demand, GRAM invested in fully integrated, top of the line equipment including a Bausch+Ströbel filling line with SKAN Isolators and an IMA lyophilizer with auto-loading capabilities. The new equipment and technology support our existing technical expertise, enhance capabilities and allow GRAM to increase throughput while maintaining an aseptic environment that continues to prioritize product integrity.


    GRAM's new facility features a fully integrated Bausch + Strobel filling line. (Photo courtesy of GRAM)
    CP: How does the new equipment technology bolster GRAM’s capabilities as a parenteral drug manufacturer?

    Nick Bykerk:
    Quality, technical expertise and customer service continue to take precedence, and GRAM has substantially invested in equipment that strengthens these focuses. After a comprehensive vetting process, GRAM chose SKAN isolators, a Bausch+Ströbel filler and an IMA lyophilizer not on account of their brand names, but because of their commitments to quality, reputations for excellence and willingness to work collaboratively. All three systems work together and were customized to fit GRAM’s unique, innovative objectives and those of the market in which it operates. GRAM is grateful for our established relationships with these partners that allow for open communication and collaborative solutions with some of the top minds in the industry.

    CP: What are some other key business highlights in the past 12 months?

    Nick Bykerk:
    In addition to our focus on the expansion and consistently providing the highest quality products to customers, our attention has been on talent acquisition—recruiting the most experienced, knowledgeable and accountable people to optimize our investments in technical expertise.

    CP: In general, how would you characterize the state of the parenteral drug manufacturing market?

    Nick Bykerk:
    Simply put: limited supply, explosive demand. Generally, the market is experiencing a high volume of consolidation and capacity is being seized for internal purposes. We also hear more and more about suppliers running into quality issues with the FDA and when combined with the removal of competition in the space, supply is greatly reduced. As the ever-evolving drug market trends toward biosimilars and generics, the demand for GRAM’s services and proven quality record of zero Form 483s on our last two inspections will continue to grow.

    CP: What are three key trends in the aseptic processing space?

    Nick Bykerk:
    There are three key trends that stand out from a technical perspective, the first being the use of science-based approaches to risk assessment and risk management. GRAM approached the design of its new facility with assessing and mitigating risk in mind. We also made it a priority to understand the product design and related process requirements as well as the associated risks.

    A second trend is the role of the barrier in isolator technology. Regulators are pushing suppliers toward isolator technology to minimize human intervention and risk. GRAM experts stay alert on recommendations from the FDA, working in conjunction with regulators to implement high quality standards.

    Lastly, a critical driver in the aseptic space is the importance of automation. Right now, many existing CDMO processes rely on batch processing. The move away from human involvement is one reason why GRAM has heavily invested in automation and integration.

    CP: What are some of the crucial issues and challenges impacting aseptic processing and parenteral drug manufacturing?

    Nick Bykerk:
    Keeping up with those three key trends are important for customers to consider when choosing a CMDO partner. Likewise, modernization of legacy facilities’ equipment and processes is a critical issue. 

    CP: What are your customers’ key concerns when they come to you as a partner?

    Nick Bykerk:
    Having a partner that is on the leading edge of technology, equipment and processes is key for customers in the aseptic space, and GRAM’s stance is that it all points back to quality. If the FDA were to eventually mandate the move to isolator technology, for example, it is an expensive process with long lead times and lengthy qualification processes. Focusing investments on quality and innovation positions CDMOs to best serve their clients.

    CP: Beyond the opening of the facility this spring, what’s next for GRAM?

    Nick Bykerk:
    Expect to see the same growth from GRAM—continuing to expand our expertise for our customer base and further tapping into numerous drug markets including biosimilars, biologics, generics and name brands—while doing more with better technology in our new facility. Our investments will help us to continue to prioritize quality, scale our systems, and employ talent that is committed to impacting people’s lives with the work GRAM does inside and outside of our facility walls. 

    CP: What about GRAM appealed to Arlington, sparking the majority investment back at the end of 2017?

    Malcolm Little:
    GRAM is well-positioned to meet the growing demand for aseptic CDMO services because of the company’s exemplary quality record, which is truly unique in the industry. Additionally, GRAM’s breadth of development and manufacturing experience across therapeutic areas at both a clinical and commercial scale provides a solid foundation from which to further grow.

    GRAM has amassed a diverse base of blue-chip customers, which supports their efforts and validates the industry’s perspective on GRAM’s capabilities. As potential investors in GRAM, establishing this same high level of confidence in the GRAM management team was a critical factor in establishing our partnership. Tom Ross, CEO of GRAM, and the rest of the GRAM team have done an exemplary job building the company with an unwavering focus on scientific innovation and quality.

    CP: What about the CDMO space in general is appealing to Arlington and why invest in the parenteral space?

    Malcolm Little:
    Arlington Capital Partners has been one of the most active investors in pharma services over the last two decades, dating back across several funds and businesses we’ve helped to grow. CDMOs benefit from a favorable macro environment, which is supported by robust pharmaceutical development as well as increased reliance on providers of high-quality outsourced services.

    Particularly in the large and growing parenteral market where demand continues to outpace supply, we are drawn to platforms like GRAM that have an established position supporting molecules across the entire product lifecycle. Significant investment in large molecule and other advanced therapies will continue to drive growth within the parenteral space.

    CP: How would you characterize the state of the CDMO industry from an investor’s perspective?

    Malcolm Little:
    The current supply and demand imbalance has attracted a lot of capital into the CDMO space, particularly in U.S. and European markets. In parenteral development and manufacturing, where GRAM operates, industry consolidation and quality issues have driven scarcity value amongst proven, high-quality platforms.

    CP: What are the key trends and challenges unique to the CDMO space and impacting the market today? 

    Malcolm Little:
    A trend we’re continuing to watch is the considerable investment in advanced therapies. Therapies involving large molecules as well as cell and gene therapies are driving demand for outsourced development, manufacturing and finishing. Many, if not all, of these therapies require services that GRAM has in place today and will be expanding upon with the new facility.

    Though not a new challenge, quality is a true differentiator and cannot be overemphasized in the CDMO space. Quality issues, particularly with offshore manufacturers, as well as supply chain challenges more generally are driving demand for domestic CDMO services, further straining existing industry capacity. This need continues to benefit businesses like GRAM that have a proven quality track record, scalable systems and the demonstrated ability to expand.  




    Nick Bykerk
    A certified public accountant, Nick Bykerk serves as GRAM’s vice president of finance. Prior to joining GRAM, Nick worked for a regional public accounting firm, where he focused on manufacturing and service companies and served in technical, management and advisory positions. After leaving public accounting, he joined a local manufacturing company as a member of the executive management team to run the finance and accounting departments. A graduate of Calvin College with a degree in public accounting, Nick joined GRAM in 2012.
     


    Malcolm Little
    Malcolm Little is a partner at Arlington Capital Partners, where he is responsible for investing in the healthcare sector, and a director of Grand River Aseptic Manufacturing. Prior to joining Arlington, Malcolm was a vice president at Avista Capital Partners where he focused primarily on investments in the healthcare industry. In addition to serving on the board of directors of GRAM, Malcolm currently serves as a director of Molecular Products and has previously been a member of the board of directors of Avalign Technologies, MicroPact and Ontario Systems. Malcolm earned an M.B.A. degree from Harvard Business School and holds a B.S. degree, with distinction, from the University of Virginia.
    Related Searches
    • automation
    • outsourced
    • Pharma
    • it

    Related Features

    • Solid Dosage/Creams/Ointments
      High Drug Loading Amorphous Solid Dispersions

      High Drug Loading Amorphous Solid Dispersions

      A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings
      Deanna Mudie and Aaron Stewart, Lonza 01.27.21

    • Parenterals
      Parenteral Drug Delivery Trends

      Parenteral Drug Delivery Trends

      A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
      Kristin Brooks, Managing Editor, Contract Pharma 01.27.21

    • Selecting the Right Outsourcing Model for Emerging Biotech

      Selecting the Right Outsourcing Model for Emerging Biotech

      Flexible outsourcing models help drive quality, control costs and enable better efficiencies and faster delivery.
      Timothy King and Elisha Talley-Roithner, PPD 01.27.21


    • Drug Delivery
      Inhaled Drug Delivery Technology

      Inhaled Drug Delivery Technology

      The success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 01.27.21

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Analytical Services | Information Technology | Laboratory Testing
      Business Intelligence For (and From) the Lab

      Business Intelligence For (and From) the Lab

      How a digital ecosystem can harness the most data-rich environment in the CDMO.
      Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21


    • Communicating Your Contracting Priorities to Your Drug Company Customers

      Communicating Your Contracting Priorities to Your Drug Company Customers

      A discussion with Perrigo’s senior legal counsel, Susan Fyan, about issues that arise in very fact-specific contract negotiations between CDMOs and sponsors.
      Stephen Sayre, Dykema 01.27.21

    • COVID-19 Impact Report

      COVID-19 Impact Report

      Leaders across the pharmaceutical contract services industry reflect on the impact of COVID-19 in 2020, and what to expect in 2021.
      Tim Wright, Editor, Contract Pharma 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21


    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    • Century Therapeutics Significantly Expands Capabilities
    • ICON Acquires Medpass
    Breaking News
    • High Purity New England Bolsters Biopharma Solutions Services
    • AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    • CatSci Opens New Site in UK
    • Pfizer Partners with Medicines Manufacturing Innovation Center
    • Covectra Introduces Next-Gen Serialization Solution
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Danone Adds to Plant-Based Portfolio with Acquisition of Follow Your Heart Brand
    Coatings World

    Latest Breaking News From Coatings World

    OQ Chemicals Increases Carboxylic Acids, Esters Prices
    Sensory Analytics Announces Issuance of Broad New Patent Covering Coating Thickness Measurement
    Arkema Reports Full-year 2020 Results
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Japan to Lead APAC Assisted Reproductive Technology Devices Market
    Portescap Slotless Brushless DC Motors Receive ISO 13485 Certification
    FDA Breakthrough Device Designation Given to MI Transcatheter Heart Pump
    Contract Pharma

    Latest Breaking News From Contract Pharma

    High Purity New England Bolsters Biopharma Solutions Services
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    CatSci Opens New Site in UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Christie Brinkley Joins SBLA Beauty
    Madison Reed Raises $52 Million in Financing Round
    The Estée Lauder Companies Closes Becca Cosmetics
    Happi

    Latest Breaking News From Happi

    MAC Cosmetics Launches Foundation
    ACI Unveils New Online Resources
    Sales More Than Double at Madison Reed
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    S-OneLP adds to growing team
    Avery Dennison expands automotive portfolio
    Amberley Labels turns to Kurz for embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Believe Diapers Launch in U.S.
    Forbes Ranks Rockline Among Best U.S. Employers
    H&V Announces Price Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    NuVasive Nabs Simplify Medical for $150M
    SeaSpine Begins Limited Launch of WaveForm TA (TLIF Articulating) 3D-Printed Interbody
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login